TG Therapeutics, Inc. - Common Stock (NQ:TGTX)

54.34 -0.93 (-1.68%)

Delayed Quote Updated: 4:00 PM EDT, Oct 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about TG Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Crude Oil Falls 1.5%; ON Semiconductor Shares Plunge After Q2 Results ↗

August 04, 2025

Via Benzinga

Briumvi's Strong Sales Can't Stop TG Therapeutics Stock Slide ↗

August 04, 2025

TG Therapeutics missed Q2 earnings and revenue expectations but raised its 2025 Briumvi sales guidance following strong global growth.

Via Benzinga

TG Therapeutics Q2 Revenue Up 91% ↗

August 04, 2025

Via The Motley Fool

Topics Intellectual Property

Why Top 3% Stock TG Therapeutics Crashed Despite Raising Its 2025 Outlook ↗

August 04, 2025

The company makes a multiple sclerosis treatment called Briumvi that rivals a drug from Roche.

Via Investor's Business Daily

Traders are paying attention to the gapping stocks in Monday's session. ↗

August 04, 2025

Let's delve into the US markets on Monday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.

Via Chartmill

Earnings Scheduled For August 4, 2025 ↗

August 04, 2025

Via Benzinga

What's Next: TG Therapeutics's Earnings Preview ↗

August 01, 2025

Via Benzinga

TG Therapeutics Inc (NASDAQ:TGTX) Reports Mixed Q2 2025 Results, Raises Full-Year BRIUMVI Revenue Guidance ↗

August 04, 2025

TG Therapeutics reported mixed Q2 2025 results, missing revenue and EPS estimates but raising full-year BRIUMVI sales guidance. Shares dipped slightly as investors weighed the outlook.

Via Chartmill

TG THERAPEUTICS INC (NASDAQ:TGTX) – A High Growth Momentum Stock with Strong Technical Setup ↗

July 17, 2025

TG THERAPEUTICS INC (NASDAQ:TGTX) shows strong earnings momentum and a bullish technical setup, making it a candidate for high-growth investors. The stock has solid revenue growth, improving margins,...

Via Chartmill

TG THERAPEUTICS INC (NASDAQ:TGTX) - A High-Growth Stock Meeting Minervini's Trend Template ↗

July 12, 2025

TG Therapeutics (TGTX) meets Minervini's Trend Template with strong technicals and high-growth fundamentals, including 1,300% EPS growth and 90% revenue expansion. A breakout above $37.27 could signal...

Via Chartmill

Cramer Backs This Mining Giant After $1.6B Bet ↗

July 01, 2025

Jim Cramer recommends buying Rio Tinto due to its high yield. TG Therapeutics is also a buy, with strong first-quarter sales and potential for market share growth.

Via Benzinga

TG THERAPEUTICS INC (NASDAQ:TGTX) - A High Growth Momentum Stock with Strong Technical Setup ↗

June 25, 2025

TG Therapeutics (TGTX) shows strong earnings momentum with 142% EPS growth and a bullish technical setup, making it a candidate for high-growth investors.

Via Chartmill

Earnings Scheduled For May 5, 2025 ↗

May 05, 2025

Via Benzinga

Why TG Therapeutics Stock Was Soaring This Week ↗

March 07, 2025

Via The Motley Fool

TG Therapeutics Boosts Retail Sentiment With Q1 Revenue Beat Even As Stock Tumbles On Profit Miss, Conservative Outlook ↗

May 05, 2025

Investors are optimistic about the company’s prospects, particularly in the multiple sclerosis market, despite challenges from competitors.

Via Stocktwits

TG Therapeutics Falls Short On Earnings, But Briumvi Sales Steal the Show ↗

May 05, 2025

TG Therapeutics posts Q1 profit and nearly doubles revenue, driven by rising Briumvi sales and higher full-year guidance for 2025.

Via Benzinga

Why TG Therapeutics Stock Was Tumbling Today ↗

May 05, 2025

Via The Motley Fool

Crude Oil Falls Over 2%; ISM Services PMI Rises In April ↗

May 05, 2025

Via Benzinga

TG Therapeutics Stock Tumbles After Q1 Earnings Fall Short Of Wall Street Estimates: But Retail’s Optimistic ↗

May 05, 2025

The company, however, raised its full-year 2025 global net revenue target to approximately $575 million, up from its previous guidance of $540 million.

Via Stocktwits

Applying Mark Minervini’s growth stock checklist to TG THERAPEUTICS INC (NASDAQ:TGTX) ↗

May 02, 2025

A fundamental and technical analysis of (NASDAQ:TGTX): Is TG THERAPEUTICS INC (NASDAQ:TGTX) suited for high growth investing?

Via Chartmill

TG Therapeutics Inc (NASDAQ:TGTX): A Strong Minervini Trend Template Candidate ↗

May 01, 2025

TG Therapeutics Inc (NASDAQ:TGTX): A Strong Minervini Trend Template Candidate

Via Chartmill

Exploring high growth characteristics of TG THERAPEUTICS INC (NASDAQ:TGTX). ↗

April 19, 2025

UA fundamental and technical analysis of (NASDAQ:TGTX): nlocking the high Growth Potential of TG THERAPEUTICS INC (NASDAQ:TGTX).

Via Chartmill

Price Over Earnings Overview: TG Therapeutics ↗

April 14, 2025

Via Benzinga

Applying Mark Minervini’s growth stock checklist to TG THERAPEUTICS INC (NASDAQ:TGTX) ↗

April 05, 2025

Why TG THERAPEUTICS INC (NASDAQ:TGTX) qualifies as a high growth stock. A fundamental and technical analysis of (NASDAQ:TGTX).

Via Chartmill

IBD 50 Stock TG Therapeutics Rallies On A Setback For Chief Rival Roche ↗

April 02, 2025

The companies both have drugs that treat relapsing forms of multiple sclerosis.

Via Investor's Business Daily

Stock Of The Day: TG Therapeutics Breaks Out, May Head Higher ↗

March 21, 2025

TG Therapeutics has broken an important resistance level. There is a good chance that they will continue to move higher.

Via Benzinga

How does TG THERAPEUTICS INC (NASDAQ:TGTX) stack up against Mark Minervini’s strategy? ↗

March 14, 2025

A fundamental and technical analysis of (NASDAQ:TGTX): Is TG THERAPEUTICS INC (NASDAQ:TGTX) suited for high growth investing?

Via Chartmill

TG THERAPEUTICS INC (NASDAQ:TGTX), a growth stock which is not overvalued. ↗

March 10, 2025

Uncover the potential of TG THERAPEUTICS INC, a growth stock reasonably priced. NASDAQ:TGTX is excelling in growth aspects, maintaining a healthy financial position, and still offers an attractive...

Via Chartmill

Bilibili, MARA And ZEEKR Are Among Top 8 Mid-Cap Gainers Last Week (Mar 3-Mar 7): Are The Others In Your Portfolio? ↗

March 09, 2025

Top mid-cap stocks jumped up to 23.87%. Some reasons include strong gold/silver, better financial results, and market strength.

Via Benzinga

Retail Bets TG Therapeutics Stock Can Sustain Post-Earnings Gains Throughout The Week ↗

March 03, 2025

Annual revenue from its MS drug, Briumvi, more than tripled, with U.S. net product revenue reaching $103.6 million in the fourth quarter and $310 million for the full year.

Via Stocktwits

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.